South Dakota statute
SDCL § 34-20B-20.2 — Xylazine--Permissible uses
Current through text effective June 30, 2026 (through the 2025 Regular Session)
Part of Chapter 20B: Drugs And Substances Control, South Dakota Codified Laws.
Full text of SDCL § 34-20B-20.2
Statutory text current through the text effective June 30, 2026 (through the 2025 Regular Session). This publication reproduces the official statutory text; it is not the official statutes of the State of South Dakota.
Any material, compound, mixture, or preparation that contains xylazine is a Schedule III controlled drug or substance, except in the following cases:
(1) Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States secretary of health and human services under 21 U.S.C. § 360b (January 1, 2024);
(2) Dispensing, prescribing, or administering xylazine to an animal that is permissible under 21 U.S.C. § 360b(a)(4) (January 1, 2024);
(3) Manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug:
(a) Approved under 21 U.S.C. § 360b (January 1, 2024); or
(b) Issued an investigation use exemption under 21 U.S.C. § 360b(j) (January 1, 2024);
(4) Manufacturing, distributing, or using a xylazine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarian; or
(5) Any other use approved or permissible under 21 U.S.C. § 301, et seq. (January 1, 2024).
Official sources
Legal terms used in this section
This reference is informational and is not legal advice.